September 6, 2006

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

Key Points

Key points are not available for this paper at this time.

Abstract

Different molecular mechanisms are responsible for primary and secondary imatinib resistance in GISTs. These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.

Mark Helpful

Bookmark

Relay

Mark Helpful

Bookmark

Relay

Cite This Study

Heinrich et al. (Wed,) studied this question.

synapsesocial.com/papers/69de8c00681d8c8a46e941d0 https://doi.org/https://doi.org/10.1200/jco.2006.06.2265

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation2005 · 831 citations
2Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants2005 · 494 citations
3Polyclonal Evolution of Multiple Secondary <i>KIT</i> Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate2006 · 365 citations
4Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala2005 · 75 citations
5Activating c-kit Gene Mutations in Human Germ Cell Tumors1999 · 412 citations